Mostrar el registro sencillo del ítem

High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMERIENNE, Camille
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorROUSSET, Marine
dc.contributor.authorDUCINT, D.
dc.contributor.authorCASTAING, N.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTITIER, Karine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOLIMARD, Mathieu
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBOUCHET, Stephane
dc.date.accessioned2020-12-07T15:38:14Z
dc.date.available2020-12-07T15:38:14Z
dc.date.issued2018-02-20
dc.identifier.issn1873-264X (Electronic) 0731-7085 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/21334
dc.description.abstractEnSeveral studies have shown that therapeutic drug monitoring of tyrosine kinase inhibitors (TKI) can improve their benefit in cancer. An analytical tool has been developed in order to quantify 17 tyrosine kinase inhibitors and 2 metabolites in human plasma (afatinib, axitinib, bosutinib, crizotinib, dabrafenib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, ponatinib, regorafenib, regorafenib M2, regorafenib M5, ruxolitinib, sorafenib, sunitinib, vandetanib). Drugs were arranged in four groups, according to their plasma concentration range: 0.1-200ng/ml, 1-200ng/ml, 4-800ng/ml and 25-5000ng/ml. Solid phase extraction was used and separation was performed with HPLC using a gradient system on a solid core particle C18 column (5x2.1mm, 1.6mum). Ions were detected with a triple quadrupole mass spectrometry system. This assay allows rapid determination of 19 TKI in less than 5min per run. This high throughput routine method will be useful to adjust doses of oral anticancer drugs in order to improve treatments efficacy.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enHigh throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS
dc.title.alternativeJ Pharm Biomed Analen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.jpba.2017.11.060en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29220734en_US
bordeaux.journalJournal of Pharmaceutical and Biomedical Analysisen_US
bordeaux.page112-120en_US
bordeaux.volume150en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03193744
hal.version1
hal.date.transferred2021-04-09T07:13:01Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&rft.date=2018-02-20&rft.volume=150&rft.spage=112-120&rft.epage=112-120&rft.eissn=1873-264X%20(Electronic)%200731-7085%20(Linking)&rft.issn=1873-264X%20(Electronic)%200731-7085%20(Linking)&rft.au=MERIENNE,%20Camille&ROUSSET,%20Marine&DUCINT,%20D.&CASTAING,%20N.&TITIER,%20Karine&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem